Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial
ContributorsCahn, Pedro; Kaplan, Richard; Sax, Paul E; Squires, Kathleen; Molina, Jean-Michel; Avihingsanon, Anchalee; Ratanasuwan, Winai; Rojas, Evelyn; Rassool, Mohammed; Bloch, Mark; Vandekerckhove, Linos; Ruane, Peter; Yazdanpanah, Yazdan; Katlama, Christine; Xu, Xia; Rodgers, Anthony; East, Lilly; Wenning, Larissa; Rawlins, Sandy; Homony, Brenda; Sklar, Peter; Nguyen, Bach-Yen; Leavitt, Randi; Teppler, Hedy; Calmy, Alexandra
Published inThe Lancet HIV, vol. 4, no. 11, p. e486-e494
Publication date2017
Abstract
Keywords
- Administration
- Oral
- Adult
- Anti-HIV Agents/administration & dosage/adverse effects/therapeutic use
- Biological Availability
- Coinfection/virology
- Double-Blind Method
- Emtricitabine/administration & dosage/adverse effects/pharmacokinetics/therapeutic use
- Female
- HIV Infections/drug therapy/virology
- HIV-1/drug effects/physiology
- Hepatitis B/virology
- Hepatitis C/virology
- Humans
- Male
- Quality of Life
- RNA
- Viral/blood/drug effects
- Raltegravir Potassium/administration & dosage/adverse effects/pharmacokinetics/therapeutic use
- Tenofovir/administration & dosage/adverse effects/pharmacokinetics/therapeutic use
- Viral Load/drug effects
Affiliation entities
Research groups
Citation (ISO format)
CAHN, Pedro et al. Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial. In: The Lancet HIV, 2017, vol. 4, n° 11, p. e486–e494. doi: 10.1016/S2352-3018(17)30128-5
Main files (1)
Article (Published version)
Identifiers
- PID : unige:112380
- DOI : 10.1016/S2352-3018(17)30128-5
- PMID : 28918877
Journal ISSN2352-3018
